Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies. Unfortunately, MM continues to cause significant morbidity and most patients eventually succumb to the disease. As in other areas of cancer...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2017-05-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1308618 |
| _version_ | 1819060843439980544 |
|---|---|
| author | Sabarinath Venniyil Radhakrishnan Neelam Bhardwaj Tim Luetkens Djordje Atanackovic |
| author_facet | Sabarinath Venniyil Radhakrishnan Neelam Bhardwaj Tim Luetkens Djordje Atanackovic |
| author_sort | Sabarinath Venniyil Radhakrishnan |
| collection | DOAJ |
| description | Treatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies. Unfortunately, MM continues to cause significant morbidity and most patients eventually succumb to the disease. As in other areas of cancer, immunotherapy in MM has also evolved and holds promise to deliver long-lasting remissions or even cure. The signaling lymphocyte activation molecules (SLAM) family of surface proteins represents a group of potential targets for immunotherapy in MM as some of the family members are expressed consistently on plasma cells and also on myeloma propagating pre-plasma cells. Here, we review the SLAM family members in detail, describe their tissue distribution, biologic pathways, as well as relevant pre-clinical studies and clinical trials in MM. Our review demonstrates the value of SLAM family receptors as potential targets for anti-myeloma immunotherapies and outlines how immunotherapeutic approaches can be developed. |
| first_indexed | 2024-12-21T14:33:26Z |
| format | Article |
| id | doaj.art-88f382b7cfd0428d979561a80fe6db0f |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-21T14:33:26Z |
| publishDate | 2017-05-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-88f382b7cfd0428d979561a80fe6db0f2022-12-21T19:00:24ZengTaylor & Francis GroupOncoImmunology2162-402X2017-05-016510.1080/2162402X.2017.13086181308618Novel anti-myeloma immunotherapies targeting the SLAM family of receptorsSabarinath Venniyil Radhakrishnan0Neelam Bhardwaj1Tim Luetkens2Djordje Atanackovic3Hematology and Hematologic Malignancies, University of Utah/Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah/Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah/Huntsman Cancer InstituteHematology and Hematologic Malignancies, University of Utah/Huntsman Cancer InstituteTreatment for multiple myeloma (MM) has significantly advanced in the last decade with the introduction of proteasome inhibitors and immunomodulatory therapies. Unfortunately, MM continues to cause significant morbidity and most patients eventually succumb to the disease. As in other areas of cancer, immunotherapy in MM has also evolved and holds promise to deliver long-lasting remissions or even cure. The signaling lymphocyte activation molecules (SLAM) family of surface proteins represents a group of potential targets for immunotherapy in MM as some of the family members are expressed consistently on plasma cells and also on myeloma propagating pre-plasma cells. Here, we review the SLAM family members in detail, describe their tissue distribution, biologic pathways, as well as relevant pre-clinical studies and clinical trials in MM. Our review demonstrates the value of SLAM family receptors as potential targets for anti-myeloma immunotherapies and outlines how immunotherapeutic approaches can be developed.http://dx.doi.org/10.1080/2162402X.2017.1308618car t cellscd229immunotherapymonoclonal antibodiesmultiple myelomaslam family of receptors |
| spellingShingle | Sabarinath Venniyil Radhakrishnan Neelam Bhardwaj Tim Luetkens Djordje Atanackovic Novel anti-myeloma immunotherapies targeting the SLAM family of receptors OncoImmunology car t cells cd229 immunotherapy monoclonal antibodies multiple myeloma slam family of receptors |
| title | Novel anti-myeloma immunotherapies targeting the SLAM family of receptors |
| title_full | Novel anti-myeloma immunotherapies targeting the SLAM family of receptors |
| title_fullStr | Novel anti-myeloma immunotherapies targeting the SLAM family of receptors |
| title_full_unstemmed | Novel anti-myeloma immunotherapies targeting the SLAM family of receptors |
| title_short | Novel anti-myeloma immunotherapies targeting the SLAM family of receptors |
| title_sort | novel anti myeloma immunotherapies targeting the slam family of receptors |
| topic | car t cells cd229 immunotherapy monoclonal antibodies multiple myeloma slam family of receptors |
| url | http://dx.doi.org/10.1080/2162402X.2017.1308618 |
| work_keys_str_mv | AT sabarinathvenniyilradhakrishnan novelantimyelomaimmunotherapiestargetingtheslamfamilyofreceptors AT neelambhardwaj novelantimyelomaimmunotherapiestargetingtheslamfamilyofreceptors AT timluetkens novelantimyelomaimmunotherapiestargetingtheslamfamilyofreceptors AT djordjeatanackovic novelantimyelomaimmunotherapiestargetingtheslamfamilyofreceptors |